ReviewCancers2022
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
Laetitia Collet et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papertrialcites it
ReviewCancers2022
Laetitia Collet et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.